AVALO THERAPEUTICS INC
AVTXNASDAQ🏆 #1969 by market capEarnings Nov 4US Equity
$550.59▼ $27.91 (−5.07%)
Simulated price1h—
24h▼ 5.1%
7d▲ 2820.9%
14d▲ 2805.5%
30d▲ 2811.6%
1y▲ 5782.4%
🏦Market Cap
$1.06B
Small Cap
📈Revenue Growth (YoY)
-86.6%
Declining
📊Gross Margin
242.2%
High
💵FCF Margin
—
⚖️P/S Ratio
17584.3x
Expensive
Otter Score
45
Weak
Trading Snapshot
- Day Range
- $543.17 – $559.04
- 52-Week Range
- $8.29 – $24.27
- Volume
- $2.36B
- Avg Volume
- $2.20B
- Shares Outstanding
- 52.9M
- Next Earnings
- Sep 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $60,296
- Last Q Revenue
- $16,517
- P/E Ratio
- —
- P/S Ratio
- 17584.3x
- EPS (TTM)
- $-6.04
- Dividend Yield
- —
Why Investors Own AVTX
- ✓High-growth profile — revenue up +43.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$60,296▲ +42.0% YoY
Gross Margin (TTM)
35.4%▲ +0.8% YoY
Operating Income (TTM)
$7,778▲ +42.0% YoY
Free Cash Flow (TTM)
$15,315▲ +42.0% YoY
About AVALO THERAPEUTICS INC
A company profile for AVALO THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Price Target
ⓘAverage Target
$577.05
▲ +4.8% Upside
High Target$680.64
Low Target$467.42
Based on 40 analysts
Latest News & Updates
🚀
CNBC·2h ago
AVALO THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift AVTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
AVALO THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.